1. Home
  2. DFH vs GENB Comparison

DFH vs GENB Comparison

Compare DFH & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dream Finders Homes Inc.

DFH

Dream Finders Homes Inc.

HOLD

Current Price

$15.90

Market Cap

1.7B

ML Signal

HOLD

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$13.42

Market Cap

1.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
DFH
GENB
Founded
2008
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.9B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
DFH
GENB
Price
$15.90
$13.42
Analyst Decision
Hold
Strong Buy
Analyst Count
2
6
Target Price
$26.00
$23.20
AVG Volume (30 Days)
568.5K
829.1K
Earning Date
05-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$4,322,848,000.00
N/A
Revenue This Year
$0.81
N/A
Revenue Next Year
$7.82
$16.58
P/E Ratio
$133.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.20
$11.00
52 Week High
$31.10
$18.18

Technical Indicators

Market Signals
Indicator
DFH
GENB
Relative Strength Index (RSI) 51.70 40.20
Support Level $13.71 $11.73
Resistance Level $16.46 $13.76
Average True Range (ATR) 0.79 0.79
MACD -0.14 -0.24
Stochastic Oscillator 58.39 5.08

Price Performance

Historical Comparison
DFH
GENB

About DFH Dream Finders Homes Inc.

Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: